What Arcutis Biotherapeutics does

Arcutis Biotherapeutics is a commercial-stage medical dermatology biopharmaceutical company founded in 2016 and headquartered in Westlake Village, California, listed on NASDAQ under ticker ARQT. The company develops and commercializes targeted topical therapies for chronic inflammatory skin diseases, with a primary focus on three indications: atopic dermatitis, plaque psoriasis, and seborrheic dermatitis. Its core asset is ZORYVE (roflumilast), a topical phosphodiesterase type 4 (PDE4) inhibitor available in cream (0.05%, 0.15%, 0.3%) and foam (0.3%) formulations, with six FDA approvals spanning pediatric and adult populations. ZORYVE is differentiated as a once-daily, steroid-free, non-greasy topical treatment that avoids sensitizing excipients and is supported by clinical data showing rapid itch relief and sustained disease control.

The company generates revenue through prescription sales of ZORYVE products, reaching $372.1M in FY2025 (+123% YoY) and $105.4M in Q1 2026 (+65% YoY), with FY2026 guidance raised to $480-495M and approximately 90% gross margins. Arcutis distributes through a direct 160-rep dermatology sales force, a 30-person primary care/pediatrics pilot team, retail and specialty pharmacy channels, and the Arcutis Cares patient assistance program. The company has a wholly-owned subsidiary, Ducentis BioTherapeutics (acquired September 2022 for up to $400M), which provides early-stage pipeline assets including the DS-234 fusion protein and ARQ-234 (CD200R agonist), the latter of which entered Phase 1a/1b clinical trials in March 2026. Arcutis serves patients (16.5M U.S. adults and 9.6M children with atopic dermatitis, plus 10M Americans with seborrheic dermatitis) and the dermatologists, primary care physicians, and pediatricians who treat them.

The company has reached commercial-stage financial inflection, generating positive operating cash flow starting in Q4 2025, with a current market capitalization of approximately $3.28B (June 2026) and analyst consensus price targets of $34-37 implying ~38% upside. Recent strategic priorities include direct sales channel buildout following termination of the Kowa Pharmaceuticals promotion agreement (January 2026), label expansion to younger pediatric populations, and pipeline advancement into biologic immuno-dermatology beyond topical roflumilast.

Name

Arcutis Biotherapeutics

Legal name

Arcutis Biotherapeutics, Inc.

Website

https://arcutis.com

Company type

Public

Founded year

2016

Operating status

Operating

Headcount range

251–500 employees

Short description

Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company that develops and markets ZORYVE (roflumilast), a topical PDE4 inhibitor approved for atopic dermatitis, plaque psoriasis, and seborrheic dermatitis across pediatric and adult patients in the United States, generating $372M in FY2025 revenue.

Ownership category

akta.pro rank

Product category

Medical Dermatology Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Perfumes, Cosmetics & Other Toilet Preparations (2844)

akta.pro primary industry

Dermatology Specialty Pharmaceuticals (HLAIACAL)

akta.pro secondary industries

Dermatology OTC & Skin Health (Acne Treatments, Eczema/Psoriasis OTC, Antifungals, Wart Removal) (CRADAMAF), Dermocosmetics & Medical-Grade Skincare (CRABAAAF), Psoriasis & Eczema Specialty Care (HLAKACAL), Topical & Dermatology Generics (HLAIABAE), Dermatology & Topical Skin Treatments (HLAIADAE), Treatment Skincare (Serums, Actives, Acne & Anti-aging) (CRABAAAB)

Keywords

• Topical dermatology treatments
• Inflammatory skin disease therapies
• Prescription pharmaceutical products
• Medical dermatology innovation
• Immuno-dermatology drug development

Headquarters

HQ city

Westlake Village

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Marketing or Sales, Personnel, Operations

Revenue model

1. ZORYVE Product Sales: Arcutis generates revenue through the sale of prescription ZORYVE products including roflumilast cream (0.05%, 0.15%, 0.3%) and foam (0.3%) formulations. Revenue is generated through prescription sales to patients with atopic dermatitis, plaque psoriasis, and seborrheic dermatitis. Q1 2026 net product revenue was $105.4 million, up 65% year-over-year.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Arcutis Biotherapeutics develops and commercializes ZORYVE (roflumilast), a topical phosphodiesterase type 4 (PDE4) inhibitor franchise for treating immune-mediated inflammatory skin diseases. ZORYVE is available in cream (0.05%, 0.15%, 0.3%) and foam (0.3%) formulations, FDA-approved for plaque psoriasis, atopic dermatitis, and seborrheic dermatitis across pediatric and adult populations. The company also has pipeline assets including ARQ-234, a CD200R agonist in Phase 1 development for atopic dermatitis.

Product overview

Arcutis Biotherapeutics is a commercial-stage medical dermatology company with a portfolio of advanced targeted topical therapies approved to treat three major inflammatory skin diseases: atopic dermatitis, plaque psoriasis, and seborrheic dermatitis. The core product is ZORYVE (roflumilast), available in cream and foam formulations at multiple dosage strengths (0.05%, 0.15%, and 0.3%). ZORYVE is a topical phosphodiesterase type 4 (PDE4) inhibitor that decreases production of pro-inflammatory mediators. The cream formulations target atopic dermatitis and plaque psoriasis across different age groups, while the foam formulation addresses scalp and body psoriasis as well as seborrheic dermatitis. The company also has a pipeline product, ARQ-234, a CD200R agonist in clinical development for atopic dermatitis.

Differentiator

Problem solved

Functional benefit

Brands

• ZORYVE: Prescription topical treatment containing roflumilast, approved for plaque psoriasis, atopic dermatitis, and seborrheic dermatitis in various formulations (cream and foam) and dosages for different age groups.

Products and services

• ZORYVE (roflumilast) Cream 0.05% Topical phosphodiesterase type 4 (PDE4) inhibitor cream approved for the topical treatment of mild to moderate atopic dermatitis in pediatric patients 2 to 5 years of age. Contains 0.05% roflumilast, specifically formulated for young children whose immune system and skin barrier are still developing.
• ZORYVE (roflumilast) Cream 0.15% Topical PDE4 inhibitor cream approved for the topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients 6 years of age and older. Once-daily, steroid-free, non-greasy topical treatment.
• ZORYVE (roflumilast) Cream 0.3% Topical PDE4 inhibitor cream approved for the treatment of plaque psoriasis, including intertriginous areas, in adults and pediatric patients 6 years of age and older.
• ZORYVE (roflumilast) Foam 0.3% Topical PDE4 inhibitor foam approved for the treatment of plaque psoriasis of the scalp and body in adults and pediatric patients 12 years of age and older, and for seborrheic dermatitis in adults and pediatric patients 9 years of age and older.
• ARQ-234 Investigational fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor (CD200R). Currently in Phase 1a/1b clinical development for treatment of moderate to severe atopic dermatitis in adults, with potential for infant and pediatric indications.

Quantifiable outcome

• 58.3% of infants achieved EASI-75 at Week 4 in INTEGUMENT-INFANT trial
• +7 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered minor and core.

• Kowa Pharmaceuticals AmericaminorChannel Partner/ Reseller/ Distributor · 23 January 2026Kowa Pharmaceuticals America promoted ZORYVE to primary care physicians and pediatricians under a five-year agreement. The partnership was mutually terminated in January 2026, with Arcutis assuming direct responsibility for sales and promotion activities. Jefferies analysts noted the Kowa partnership had small or immaterial sales impact. Arcutis will not be required to make further payments to Kowa.
• Huadong PharmaceuticalminorStrategic or Co-development PartnerCollaboration and licensing agreement with Huadong Pharmaceutical covering China and Greater Asia for ZORYVE. Generated $2.0 million in license revenues in Q1 2025.
• LifeArc / Ducentis BioTherapeuticscoreStrategic or Co-development PartnerArcutis acquired Ducentis BioTherapeutics Ltd. (a LifeArc portfolio company) in September 2022 for up to $400 million including upfront and contingent payments. Ducentis' lead asset DS-234 is a fusion protein targeting immune regulation via checkpoint agonism for atopic dermatitis. The ~$30 million initial payment was made with potential milestone payments.

Scale indicators12 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Pfizer: Pfizer markets Eucrisa (crisaborole), a topical PDE4 inhibitor approved for mild-to-moderate atopic dermatitis. Directly comparable to ZORYVE in mechanism (PDE4 inhibition), therapeutic area, and pediatric indication, making it the closest head-to-head competitor.
• Incyte: Incyte commercializes Opzelura (ruxolitinib cream), a topical JAK inhibitor approved for atopic dermatitis and vitiligo. Targets the same mild-to-moderate atopic dermatitis prescriber base as ZORYVE with a differentiated mechanism, making it a direct competitor for the same prescription volume.
• Organon (Dermavant): Organon acquired Dermavant and markets Vtama (tapinarof) cream for plaque psoriasis, with atopic dermatitis in development. Competes head-to-head with ZORYVE in plaque psoriasis and represents a near-term entrant into the topical atopic dermatitis space.
• LEO Pharma: LEO Pharma markets Adbry (tralokinumab) for atopic dermatitis and a broader topical dermatology portfolio. Competes with ZORYVE in atopic dermatitis via a different mechanism (IL-13 biologic), and shares the dermatology-specialist commercial channel.

Broad incumbents

• Bristol-Myers Squibb: BMS markets Sotyktu (deucravacitinib), an oral TYK2 inhibitor approved for plaque psoriasis. Competes with ZORYVE in plaque psoriasis via systemic therapy and is expanding into adjacent dermatology indications.
• AbbVie: AbbVie markets Skyrizi (risankizumab) and Rinvoq (upadacitinib), both approved in psoriasis and atopic dermatitis. Represents systemic-therapy competition to ZORYVE, particularly in moderate-to-severe patients, and has substantially larger commercial resources.
• Galderma: Galderma is a global dermatology pure-play with a broad prescription and consumer skincare portfolio across psoriasis, atopic dermatitis, and acne. Overlaps with Arcutis across multiple therapeutic and aesthetic categories and competes for the same dermatology prescriber channel.
• Sanofi / Regeneron: Sanofi and Regeneron co-market Dupixent (dupilumab), the dominant biologic for moderate-to-severe atopic dermatitis. Defines the standard of care in moderate-to-severe disease and indirectly shapes prescriber preferences in the mild-to-moderate segment where ZORYVE competes.

Emerging players

• UCB: UCB markets bimekizumab (Bimzelx) in psoriasis and is expanding in dermatology indications. An emerging immunology player whose IL-17 pathway competes with ZORYVE in plaque psoriasis.
• Vyne Therapeutics: Vyne Therapeutics is a clinical-stage dermatology company developing topical therapies for inflammatory skin diseases including atopic dermatitis. Smaller and earlier-stage than Arcutis but addresses the same prescriber base and therapeutic categories.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/ArcutisBi
• Facebookfacebook.com/Arcutis-Biotherapeutics-102158242432753
• LinkedInlinkedin.com/company/arcutis-inc
• Instagraminstagram.com/arcutisbio

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries2 records

Funding overview

Funding rounds8 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arcutis Biotherapeutics